OptiBiotix Health (OB3) Ratios
OptiBiotix Health Ratios
DE:OB3's free cash flow for Q2 2026 was $-834.00K. For the 2026 fiscal year, DE:OB3's free cash flow was increased by $0.00 and operating cash flow was $-834.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Jun 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.27 | 3.87 | 7.67 | 6.68 | 6.41 |
| Quick Ratio | 3.49 | 3.24 | 6.62 | 6.04 | 6.24 |
| Cash Ratio | 2.70 | 2.01 | 3.53 | 3.78 | 3.34 |
| Solvency Ratio | -6.04 | -2.47 | -3.45 | 4.37 | 3.32 |
| Operating Cash Flow Ratio | -4.61 | -4.80 | -8.48 | -3.99 | -2.60 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 1.03M | $ 776.00K | $ 848.00K | $ 1.21M | $ 1.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Financial Leverage Ratio | 1.10 | 1.08 | 1.06 | 1.06 | 1.11 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 137.44 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -28.44 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net Debt to EBITDA | 0.35 | 0.36 | 0.35 | -0.38 | -0.18 |
| Profitability Margins | |||||
| Gross Profit Margin | 52.66% | 38.05% | 49.69% | 53.39% | 50.75% |
| EBIT Margin | -268.61% | -260.46% | -317.24% | 552.30% | 281.29% |
| EBITDA Margin | -251.03% | -236.44% | -285.40% | 601.31% | 294.31% |
| Operating Profit Margin | -268.61% | -260.46% | -263.20% | -544.64% | -61.68% |
| Pretax Profit Margin | -338.16% | -214.48% | -317.24% | 534.14% | 279.12% |
| Net Profit Margin | -333.62% | -207.47% | -316.61% | 566.08% | 282.92% |
| Continuous Operations Profit Margin | -333.62% | -207.47% | -316.61% | 566.08% | 282.92% |
| Net Income Per EBT | 98.66% | 96.73% | 99.80% | 105.98% | 101.36% |
| EBT Per EBIT | 125.89% | 82.35% | 120.53% | -98.07% | -452.53% |
| Return on Assets (ROA) | -56.44% | -19.96% | -21.68% | 22.40% | 31.08% |
| Return on Equity (ROE) | -61.92% | -21.49% | -22.98% | 23.72% | 34.52% |
| Return on Capital Employed (ROCE) | -48.13% | -26.12% | -18.38% | -22.09% | -6.98% |
| Return on Invested Capital (ROIC) | -47.48% | -25.26% | -18.34% | -22.09% | -6.98% |
| Return on Tangible Assets | -65.05% | -22.77% | -25.26% | 25.85% | 35.77% |
| Earnings Yield | -56.95% | -10.24% | -8.45% | 22.12% | 15.54% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.82 | 2.01 | 1.40 | 0.73 | 1.27 |
| Payables Turnover | 3.25 | 2.00 | 5.79 | 1.12 | 2.60 |
| Inventory Turnover | 1.85 | 2.34 | 1.72 | 1.20 | 10.70 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.17 | 0.10 | 0.07 | 0.04 | 0.11 |
| Working Capital Turnover Ratio | 1.01 | 0.77 | 0.46 | 0.19 | 0.93 |
| Cash Conversion Cycle | 180.77 | 154.57 | 409.42 | 478.50 | 181.09 |
| Days of Sales Outstanding | 95.48 | 181.66 | 260.71 | 500.78 | 287.60 |
| Days of Inventory Outstanding | 197.71 | 155.75 | 211.79 | 305.02 | 34.11 |
| Days of Payables Outstanding | 112.41 | 182.84 | 63.09 | 327.30 | 140.62 |
| Operating Cycle | 293.18 | 337.41 | 472.50 | 805.80 | 321.72 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.02 | -0.02 | -0.01 | -0.02 |
| Free Cash Flow Per Share | -0.02 | -0.02 | -0.02 | -0.01 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | -1.00 | 0.00 | 0.00 | -6.60 | -8.09 |
| Capital Expenditure Coverage Ratio | -1.00 | 0.00 | 0.00 | -6.60 | -8.09 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -1.91 |
| Operating Cash Flow to Sales Ratio | -1.52 | -2.03 | -2.37 | -2.43 | -0.71 |
| Free Cash Flow Yield | -25.91% | -10.03% | -6.33% | -10.92% | -4.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.76 | -9.78 | -11.83 | 4.52 | 6.43 |
| Price-to-Sales (P/S) Ratio | 5.86 | 20.26 | 37.46 | 25.60 | 18.20 |
| Price-to-Book (P/B) Ratio | 1.09 | 2.10 | 2.72 | 1.07 | 2.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.86 | -9.97 | -15.80 | -9.16 | -22.91 |
| Price-to-Operating Cash Flow Ratio | -3.86 | -9.97 | -15.80 | -10.55 | -25.75 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | 0.53 | 0.07 | -0.08 | 0.86 |
| Enterprise Value Multiple | -1.98 | -8.21 | -12.78 | 3.87 | 6.00 |
| Enterprise Value | 5.79M | 16.88M | 23.49M | 10.65M | 39.10M |
| EV to EBITDA | -1.98 | -8.21 | -12.78 | 3.87 | 6.00 |
| EV to Sales | 4.97 | 19.41 | 36.48 | 23.29 | 17.67 |
| EV to Free Cash Flow | -3.27 | -9.55 | -15.38 | -8.34 | -22.24 |
| EV to Operating Cash Flow | -3.27 | -9.55 | -15.38 | -9.60 | -24.99 |
| Tangible Book Value Per Share | 0.05 | 0.07 | 0.08 | 0.11 | 0.18 |
| Shareholders’ Equity Per Share | 0.06 | 0.09 | 0.10 | 0.12 | 0.21 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.03 | 0.00 | -0.06 | -0.01 |
| Revenue Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 |
| Net Income Per Share | -0.04 | -0.02 | -0.02 | 0.03 | 0.07 |
| Tax Burden | 0.99 | 0.97 | 1.00 | 1.06 | 1.01 |
| Interest Burden | 1.26 | 0.82 | 1.00 | 0.97 | 0.99 |
| Research & Development to Revenue | 0.27 | 0.34 | 0.06 | 0.15 | 0.03 |
| SG&A to Revenue | 0.46 | 0.75 | 2.63 | 1.82 | 0.45 |
| Stock-Based Compensation to Revenue | 0.91 | 0.05 | 0.01 | 0.02 | 0.03 |
| Income Quality | 0.57 | 0.78 | 0.75 | 0.45 | 1.15 |
Currency in GBP
